Atomoxetine (Strattera) for attention deficit hyperactivity disorder

References

Citations

1. Allen AJ, et al. (2005). Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology, 65(12): 1941–1949.

2. Greydanus DE, et al. (2003). Attention-deficit/hyperactivity disorder in children and adolescents: Interventions for a complex costly clinical conundrum. Pediatric Clinics of North America, 50(5): 1049–1092.

3. U.S. Food and Drug Administration (2005). FDA issues public health advisory on Strattera (atomoxetine) for attention deficit disorder. FDA News P05-65. Available online: http://www.fda.gov/bbs/topics/NEWS/2005/NEW01237.html.

Author:	Jeannette Curtis	Last Updated: April 17, 2008
Medical Review:	Michael J. Sexton, MD - Pediatrics Mina Dulcan, MD - Child and Adolescent Psychiatry
© 1995-2008 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.